Shopping Cart 0
Cart Subtotal
USD 0

Spinal Cord Injury - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Spinal Cord Injury-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury-Pipeline Review, H2 2018, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 6, 9, 1, 27 and 4 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 14 molecules, respectively.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Spinal Cord Injury-Overview 6

Spinal Cord Injury-Therapeutics Development 7

Spinal Cord Injury-Therapeutics Assessment 18

Spinal Cord Injury-Companies Involved in Therapeutics Development 30

Spinal Cord Injury-Drug Profiles 43

Spinal Cord Injury-Dormant Projects 176

Spinal Cord Injury-Discontinued Products 180

Spinal Cord Injury-Product Development Milestones 181

Appendix 191


List Of Figure

List of Figures

Number of Products under Development for Spinal Cord Injury, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Spinal Cord Injury, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Spinal Cord Injury-Pipeline by AbbVie Inc, H2 2018

Spinal Cord Injury-Pipeline by Asterias Biotherapeutics Inc, H2 2018

Spinal Cord Injury-Pipeline by Athersys Inc, H2 2018

Spinal Cord Injury-Pipeline by BioArctic AB, H2 2018

Spinal Cord Injury-Pipeline by BioAxone BioSciences Inc, H2 2018

Spinal Cord Injury-Pipeline by CSL Ltd, H2 2018

Spinal Cord Injury-Pipeline by CSPC Pharmaceutical Group Limited, H2 2018

Spinal Cord Injury-Pipeline by Hemostemix Inc, H2 2018

Spinal Cord Injury-Pipeline by Histocell SL, H2 2018

Spinal Cord Injury-Pipeline by K-Stemcell Co Ltd, H2 2018

Spinal Cord Injury-Pipeline by Kadimastem Ltd, H2 2018

Spinal Cord Injury-Pipeline by Kolon TissueGene Inc, H2 2018

Spinal Cord Injury-Pipeline by Kringle Pharma Inc, H2 2018

Spinal Cord Injury-Pipeline by Mapreg SAS, H2 2018

Spinal Cord Injury-Pipeline by NervGen Pharma Corp, H2 2018

Spinal Cord Injury-Pipeline by Neuralstem Inc, H2 2018

Spinal Cord Injury-Pipeline by Neuronax SAS, H2 2018

Spinal Cord Injury-Pipeline by New World Laboratories Inc, H2 2018

Spinal Cord Injury-Pipeline by Nipro Corp, H2 2018

Spinal Cord Injury-Pipeline by Pharmicell Co Ltd, H2 2018

Spinal Cord Injury-Pipeline by PixarBio Corp, H2 2018

Spinal Cord Injury-Pipeline by RDD Pharma Ltd, H2 2018

Spinal Cord Injury-Pipeline by ReNetX Bio, H2 2018

Spinal Cord Injury-Pipeline by RespireRx Pharmaceuticals Inc, H2 2018

Spinal Cord Injury-Pipeline by SanBio Inc, H2 2018

Spinal Cord Injury-Pipeline by Stemedica Cell Technologies Inc, H2 2018

Spinal Cord Injury-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018

Spinal Cord Injury-Pipeline by Tumorend LLC, H2 2018

Spinal Cord Injury-Pipeline by Vertex Pharmaceuticals Inc, H2 2018

Spinal Cord Injury-Pipeline by Vicore Pharma AB, H2 2018

Spinal Cord Injury-Dormant Projects, H2 2018

Spinal Cord Injury-Dormant Projects, H2 2018 (Contd..1), H2 2018

Spinal Cord Injury-Dormant Projects, H2 2018 (Contd..2), H2 2018

Spinal Cord Injury-Dormant Projects, H2 2018 (Contd..3), H2 2018

Spinal Cord Injury-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Spinal Cord Injury Therapeutic Products under Development, Key Players in Spinal Cord Injury Therapeutics, Spinal Cord Injury Pipeline Overview, Spinal Cord Injury Pipeline, Spinal Cord Injury Pipeline Assessment


Companies

AbbVie Inc

Asterias Biotherapeutics Inc

Athersys Inc

BioArctic AB

BioAxone BioSciences Inc

CSL Ltd

CSPC Pharmaceutical Group Limited

Hemostemix Inc

Histocell SL

K-Stemcell Co Ltd

Kadimastem Ltd

Kolon TissueGene Inc

Kringle Pharma Inc

Mapreg SAS

NervGen Pharma Corp

Neuralstem Inc

Neuronax SAS

New World Laboratories Inc

Nipro Corp

Pharmicell Co Ltd

PixarBio Corp

RDD Pharma Ltd

ReNetX Bio

RespireRx Pharmaceuticals Inc

SanBio Inc

Stemedica Cell Technologies Inc

Sumitomo Dainippon Pharma Co Ltd

Tumorend LLC

Vertex Pharmaceuticals Inc

Vicore Pharma AB